News and Press Releases
Our Research Approach CF Foundation Provides Up to $3.9M to TB Alliance to Further Develop an NTM Drug

The Cystic Fibrosis Foundation is providing additional funds to TB Alliance to advance the development of a compound that could be used to treat infections caused by nontuberculous mycobacteria.

| 2 min read
Our Advocacy Work CF Foundation Advocates to Protect Needs of People With CF in Post-Pandemic Medicaid Redeterminations

Medicaid beneficiaries are encouraged to update their information with Medicaid to ensure continued coverage.

| 5 min read
CFTR Modulators FDA Approves Kalydeco for Infants as Young as 1 Month

The U.S. Food and Drug Administration approved Kalydeco® (ivacaftor) for infants as young as 1 month who have at least one copy of 97 mutations that have proven to be responsive to Kalydeco.

| 4 min read
About the CF Foundation | Our Advocacy Work Organizations Focused on Fight Against Superbugs Celebrate Reintroduction of the PASTEUR Act

Groups urging need for revitalizing antimicrobial development call for passage of the bill this year

| 3 min read
CFTR Modulators FDA Approves Trikafta for Children Ages 2 Through 5 Years With Certain CF Mutations

With this approval, approximately 2,250 children in the U.S. will be eligible for Trikafta® (elexacaftor/tezacaftor/ivacaftor), including more than 900 who will have access to a CFTR modulator for the first time. The Cystic Fibrosis Foundation believes it is beneficial to start people with cystic fibrosis on modulators as early as possible to help prevent lung damage and the onset of complications.

| 3 min read
Advocacy The CF Foundation Urges Congress to Prioritize Access to Care in Debt Ceiling Package

Proposed policies would impose significant barriers and add burden for people with CF

| 3 min read
About the CF Foundation Cystic Fibrosis Foundation Announces Yvonne Massenburg as Next Chief People Officer

Human resources veteran Massenburg brings more than 20 years of leadership experience in nonprofit and business sectors

| 3 min read
Our Research Approach Cystic Fibrosis Foundation Commits Up to $15.5M in Additional Funding for Potential Enzyme Therapy

Funding will support clinical trials for therapy that could help improve digestion in people with CF

| 3 min read
About the CF Foundation Cystic Fibrosis Foundation Announces Kathryn Brown as Next Chief Communications and Marketing Officer

Brown to join Foundation in April 2023, bringing more than 20 years of experience in nonprofit communications and journalism, with a focus on health and science

| 4 min read
About the CF Foundation | Our Research Approach CF Foundation Invests Up to $2 Million in Nanite Inc. to Explore a New Method to Deliver Genetic Therapies to the Lung

Delivery of genetic therapies to affected tissues is a key challenge to developing new treatments for people with cystic fibrosis. In addition to investing in viral delivery and lipid nanoparticles, the Cystic Fibrosis Foundation is looking at the potential of a relatively new approach to delivery using an exceptionally small synthetic molecule called a polymer nanoparticle.

| 2 min read